CHROMADEX CORPORATION REPORTS 2017 FINANCIAL RESULTS -Fourth Quarter 2017 Net Revenues Increased by 69% to $7.5 Million

CHROMADEX CORPORATION REPORTS 2017 FINANCIAL RESULTS

-Fourth Quarter 2017 Net Revenues Increased by 69% to $7.5 Million

IRVINE, Calif., March 8, 2018 (GLOBE NEWSWIRE) - ChromaDex Corporation (NASDAQ: CDXC),

science-based, integrated nutraceutical company devoted to

improving the way people age, announced today fourth quarter and

full year 2017 financial results.

Results of operations for the three months ended Dec. 30,

three months ended Dec. 30, 2017 ( Q4 2017 ), ChromaDex

reported net sales from continuing operations of $7.5 million, up

69% compared to $4.5 million from continuing operations in the

fourth quarter of 2016. The increase in fourth quarter revenues was

driven by growth in sales of TRU NIAGEN .

profit improved in the fourth quarter of 2017 to 50.9% as compared

to 45.1% for the same period in 2016. We experienced better margins

due to the positive impact of TRU NIAGEN consumer product

sales, which we anticipate will continue.

expenses were $12.6 million in the fourth quarter of 2017, compared

to $4.2 million from continuing operations in the same period for

2016. The increase in operating expenses for fourth quarter was the

result of our strategic decision to invest in marketing to build

out the TRU NIAGEN brand, as well as legal costs associated

with ongoing litigation and higher stock-based compensation

loss attributable to common stockholders for the fourth quarter of

2017 was $8.8 million or ($0.17) per share as compared to a net

loss of $2.1 million or ($0.06) per share for Q4 2016. The higher

losses in the fourth quarter were the result of the strategic

decision to invest ahead of growth, higher legal fees associated

with ongoing litigation and higher stock-based compensation

expense, partially offset by higher sales volume and gross

fourth quarter of 2017, the reported loss from continuing

operations was negatively impacted by a non-cash charge of $3.4

million related to stock-based compensation.

EBITDA, a non-GAAP measure, was ($5.2) million for Q4 2017,

compared to adjusted EBITDA of ($1.7) million for Q4 2016.

ChromaDex defines Adjusted EBITDA as net income (loss) adjusted for

income tax, interest, depreciation, amortization and non-cash stock

compensation costs. The Basic and Diluted Adjusted EBITDA per share

for Q4 2017 was ($0.10) versus ($0.05) for Q4 2016.

ended the fourth quarter of 2017 with a solid balance sheet with

quarter-end cash of $45.4 million.

continue to see validation from the research community, as evidence

builds through peer-reviewed publications, said Frank

Jaksch, Jr., CEO and co-founder of ChromaDex. Our undisputed

leadership in NAD research will be the foundation of continued

growth for TRU NIAGEN.

Fried, President and Chief Operating Officer commented: It

has been less than a year since we made the strategic decision to

focus on TRU NIAGEN and NAD. We are very pleased with the increase

in gross margin which reflects the growing value of the TRU NIAGEN

brand. Our strategy is thus far playing out ahead of

Results of operations for the year ended Dec. 30, 2017

full year 2017, net revenues were $21.2 million from continuing

operations, down 2% compared to $21.7 million from continuing

operations for full year 2016 as the Company shifted to an

integrated global consumer product nutraceutical

profit improved in the full year 2017 to 49.4% as compared to 48.0%

for the same period in 2016. We experienced slightly better margins

due to the positive impact of TRU NIAGEN consumer

full year 2017, operating expenses from continuing operations were

$26.9 million, compared to $13.3 million from continuing operations

for full year 2016 as we invested in marketing expenditures to

build out the TRU NIAGEN brand. The increase in operating

expenses was also due to legal costs associated with ongoing

litigation and higher stock-based compensation

loss attributable to common stockholders for full year 2017 was

$11.4 million or ($0.26) per share as compared to a net loss of

$2.9 million or ($0.08) per share for full year 2016.

EBITDA a non-GAAP measure, was ($5.9) million for 2017, compared to

adjusted EBITDA of ($0.9) million for 2016. The Basic and Diluted

Adjusted EBITDA per share for 2017 was ($0.13) versus ($0.03) for

2018, the Company expects to show significant growth in sales

driven by our U.S. ecommerce and Watsons business and the launch of

TRU NIAGEN in new international markets. We expect the growth

to be skewed toward the second half of the year. We will continue

to invest in marketing expenditures to build out the TRU

NIAGEN brand, infrastructure, and new capabilities to support

Investor Conference Call

management will host an investor conference call to discuss the

year end results and provide a general business update on Thurs.,

March 8, at 4:30pm ET.

should call in at least 10 minutes prior to the call. The dial-in

information is as follows:

webcast replay will be available after the completion of the call

on the Investor Relations section of the Company website,

earnings press release, and its accompanying financial exhibits,

will be available on the Investor Relations section of the Company

website, www.chromadex.com.

About Non-GAAP Financial Measures

non-GAAP financial measures exclude interest, tax, depreciation,

amortization and share-based compensation. ChromaDex used

these non-GAAP measures when evaluating its financial results as

well as for internal resource management, planning and forecasting

purposes. These non-GAAP measures should not be viewed in isolation

from or as a substitute for ChromaDex's financial results in

accordance with GAAP. A reconciliation of GAAP to non-GAAP measures

is attached to this press release.

ChromaDex Corp. is an integrated, global nutraceutical

company devoted to improving the way people

age. ChromaDex scientists partner with leading